Transient Cold Agglutinins in a Patient With COVID-19.

anemia blood coagulation cold agglutinins covid -19 severe acute respiratory syndrome coronavirus 2

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
17 Jan 2021
Historique:
entrez: 1 3 2021
pubmed: 2 3 2021
medline: 2 3 2021
Statut: epublish

Résumé

Coronavirus disease 2019 (COVID-19) infection has been associated with various complications such as acute respiratory distress syndrome, acute kidney failure, myocardial infection, and thromboembolism. Cold agglutinin syndrome (CAS) has been associated with other viral infections such as Epstein-Barr virus (EBV), but there have been only a few reports of cold agglutination associated with COVID-19. In this report, we describe a case of transient cold agglutinin elevation in a COVID-19-infected patient. A 61-year-old man with hypertension, diabetes mellitus, and end-stage renal disease (ESRD) presented with shortness of breath, cough, and lethargy for five days. A clinical diagnosis of COVID-19 infection was made. The COVID-19 RNA qualitative real-time polymerase-chain-reaction (PCR) assay tested positive. During the hospital stay, he had progressive dyspnea requiring intubation and mechanical ventilation. During the third week of hospital stay, an acute drop in the hemoglobin (Hb) level to 4.5 g/dl (baseline Hb: 9 g/dl) was observed. The workup for acute anemia revealed a positive result for cold agglutinins, direct antibody test (C3d), and agglutination of the red blood cells were apparent on the peripheral blood smear. Further, cold agglutinin titers peaked during the third week of the onset of illness and significantly declined during the fifth week. These observational findings indicate that cold agglutinin titers might correlate with the disease activity.

Identifiants

pubmed: 33643726
doi: 10.7759/cureus.12751
pmc: PMC7885958
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e12751

Informations de copyright

Copyright © 2021, Kaur et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Science. 1943 Feb 12;97(2511):167
pubmed: 17757844
J Clin Invest. 1945 Jul;24(4):490-6
pubmed: 16695237
Cytokine Growth Factor Rev. 2020 Jun;53:66-70
pubmed: 32418715
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
J Clin Invest. 1945 Jul;24(4):458-73
pubmed: 16695234
Br J Haematol. 2020 Jul;190(1):29-31
pubmed: 32374906
N Engl J Med. 2020 Apr 30;382(18):e43
pubmed: 32294340
Clin Lymphoma. 2005 Mar;5(4):290-3
pubmed: 15794868
Blood Rev. 2012 May;26(3):107-15
pubmed: 22330255
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):226-231
pubmed: 27913484
Br J Haematol. 2020 Aug;190(4):e183-e184
pubmed: 32460350
J Clin Invest. 1945 Jul;24(4):451-7
pubmed: 16695233
Dtsch Med Wochenschr. 1977 Jan 28;102(4):125-9
pubmed: 832592
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Br J Anaesth. 2014 Dec;113(6):922-34
pubmed: 24972790
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022

Auteurs

Jasmeet Kaur (J)

Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, USA.

Swathi Mogulla (S)

Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, USA.

Rafiullah Khan (R)

Hematology and Oncology, University of Cincinnati Medical Center, Cincinnati, USA.

Geetha Krishnamoorthy (G)

Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, USA.

Sandeep Garg (S)

Hematology and Medical Oncology, St. Joseph Mercy Oakland Hospital, Pontiac, USA.

Classifications MeSH